Govt announces first-of-its-kind ph 3 ayurvedic trial for Rheumatoid Arthritis

govt-announces-first-of-its-kind-ph-3-ayurvedic-trial-for-rheumatoid-arthritis
image credit- shutterstock

To take ayurveda research in rheumatology to a global stage

Ministry of Ayush is conducting the world’s first multicentre phase III clinical trial examining the efficacy of Ayurveda in the treatment of Rheumatoid Arthritis.

The clinical trial will be conducted in accordance with stringent International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use – Good Clinical Practice (ICH- GCP) guidelines and is being closely monitored by Dr Daniel Erick Furst, a renowned rheumatologist at University of California los Angeles in the United States of America.

This project is one of the first multi-centre phase III double blind double dummy clinical trials on the efficacy of Ayurveda in the management of Rheumatoid Arthritis. This will be conducted by AVP Research Foundation, a research institution affiliated with The Arya Vaidya Pharmacy (Coimbatore) Ltd and the Central Council for Research in Ayurveda (CCRAS), a government of India agency under the Ministry of Ayush. 

Dr. M.N. Shubhashree, Research Officer, Central Ayurveda Research Institute for Metabolic Disorders, Bengaluru, “The study is expected to begin in May 2022 and is expected to be completed in next two years. The sample size has increased almost 5 times, from 48 patients to 240.”

 

Read Previous

Diageo India acquires strategic minority stake in Nao Spirits & Beverages for Rs 31.5 Cr

Read Next

Roquette invests €25 M in polyols production for healthier food

Leave a Reply